Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the nurses' health study II

Archives of Internal Medicine

Volumn 169, Issue 2, 2009, Pages 115-121

  Eliassen, A Heather ^a,b,e   Chen, Wendy Y ^a,c,d   Spiegelman, Donna ^b   Willett, Walter C ^a,b   Hunter, David J ^a,b   Hankinson, Susan E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Epidemiology ^*  (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CHEMOPROPHYLAXIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ACETAMINOPHEN; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; PREMENOPAUSE; RISK FACTORS;

EID: 58849100335     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.537     Document Type: Article

References (43)

1. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18): 2018-2024.
2. Dube C, Rostom A, Lewin G, et al; U.S. Preventive Services Task Force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146 (5):365-375.
3. Rostom A, Dube C, Lewin G, et al; U.S. Preventive Services Task Force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146(5):376-389.
4. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266.
5. Grösch S, MaierTJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98(11):736-747.
6. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89(12):2637-2645.
7. Lee PP, Ip MM. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenaseand lipoxygenase. Prostaglandins Leukot Essent Fatty Acids. 1992;45(1):21-31.
8. Robertson FM, Parrett ML, Joarder FS, et al. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 1998;122(1-2):165-175.
9. Ackerstaff E, Gimi B, Artemov D, Bhujwalla ZM. Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia. 2007;9(3):222-235.
10. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N, Otsuki Y. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res. 2006;26(6B):4245-4254.
11. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996;137 (12):5739-5742.
12. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumorcells. Prostaglandins Other Lipid Mediat. 2006;81(1-2):55-70.
13. Díaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab. 2005;90(5):2563-2570.
14. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973;36(2):207-214.
15. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(1) (suppl):277-282.
16. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord. 2007;8(3):229-239.
17. de Ziegler D, Mattenberger C, Luyet C, Romoscanu I, Irion NF, Bianchi-Demicheli F. Clinical use of aromatase inhibitors (AI) in premenopausal women [published retraction appears in J Steroid Biochem Mol Biol. 2008;110(3-5):295]. J Steroid Biochem Mol Biol. 2005;95(1-5):121-127.
18. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology. 2005;68(1):40-47.
19. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol. 2005;162(2):165-170.
20. Harris RE, Namboodiri KK, FarrarWB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7(2):203-205.
21. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2001; 10(11):1213-1217.
22. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptorstatus with breast cancer risk. JAMA. 2004; 291(20):2433-2440.
23. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between nonsteroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancerand carcinoma in situ of the breast. Cancer Causes Control. 2003;14(10):915-922.
24. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006;6: 27.
25. Slattery ML, Curtin K, Baumgartner R, et al. IL6, aspirin, nonsteroidal antiinflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev. 2007;16(4):747-755.
26. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol. 2007; 166(6):709-716.
27. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequentuse of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159.
28. García Rodríguez LA, González-Pérez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004;91(3):525-529.
29. Harris RE, Chlebowski RT, Jackson RD, et al; Women's Health Initiative. Breast cancerand nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63(18):6096-6101.
30. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1586-1591.
31. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal antiinflammatory drugs and breast cancer. Oncol Rep. 1999;6(1):71-73.
32. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138-146.
33. Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal antiinflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(1):261-264.
34. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-615.
35. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294(1):47-55.
36. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805-812.
37. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996; 88(14):988-993.
38. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299(6710):1247-1250.
39. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2008;109(3):533-543.
40. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83(1):112-120.
41. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer. 2007;121(1):211-215.
42. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of selfreported menopausal status in a prospective cohort study. Am J Epidemiol. 1987;126(2):319-325.
43. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914-923.